Related Experiment Video
Updated: Jul 3, 2025

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
Published on: November 28, 2019
Epigenetic underpinnings of tumor-immune dynamics in prostate cancer immune suppression
Duminduni Hewa Angappulige1, Nupam P Mahajan2, Kiran Mahajan2
1Division of Urologic Surgery, Washington University in St. Louis, St. Louis, MO 63110, USA; Department of Surgery, Washington University in St. Louis, St. Louis, MO 63110, USA.
Abstract:
Prostate cancer (PC) is immunosuppressive and refractory to immunotherapy. Infiltration of myeloid-derived suppressor cells (MDSCs) and senescent-like neutrophils and T cell exhaustion are observed in the tumor microenvironment (TME) following androgen receptor (AR) antagonism with antiandrogens or androgen ablation. De novo post-translational acetylation of the AR, HOXB13, and H2A at K609, K13, and K130, respectively, and phosphorylation of H4 at Y88 have emerged as key epigenetic modifications associated with castration-resistant PC (CRPC). The resulting chromatin changes are integrated into cellular processes via phosphorylation of the AR, ACK1, ATPF1A, and SREBP1 at Y267, Y284, Y243/Y246, and Y673/Y951, respectively. In this review, we discuss how these de novo epigenetic alterations drive resistance and how efforts aimed at targeting these regulators may overcome immune suppression observed in PC.
Insights
Prostate cancer (PC) becomes resistant to treatment due to epigenetic changes that suppress the immune system. Targeting these epigenetic regulators may help overcome treatment resistance in PC.
Area of Science:
- Oncology
- Immunology
- Epigenetics
Background:
- Prostate cancer (PC) is characterized by an immunosuppressive tumor microenvironment (TME).
- Androgen receptor (AR) antagonism leads to myeloid-derived suppressor cells (MDSCs), senescent neutrophils, and T cell exhaustion in the TME.
- Castration-resistant PC (CRPC) is associated with specific epigenetic modifications.
Purpose of the Study:
- To review the role of de novo epigenetic alterations in driving resistance in prostate cancer.
- To discuss how targeting epigenetic regulators can overcome immune suppression in PC.
Main Methods:
- Review of existing literature on epigenetic modifications in prostate cancer.
- Analysis of de novo post-translational acetylation and phosphorylation events.
- Examination of the integration of chromatin changes into cellular processes.
Main Results:
- De novo acetylation of AR, HOXB13, and H2A, and phosphorylation of H4 are key epigenetic events in CRPC.
- These epigenetic changes are integrated via phosphorylation of AR, ACK1, ATPF1A, and SREBP1.
- Epigenetic alterations contribute to immune suppression and treatment resistance in PC.
Conclusions:
- De novo epigenetic alterations are crucial drivers of resistance in prostate cancer.
- Targeting these epigenetic regulators presents a potential strategy to overcome immune suppression and enhance immunotherapy efficacy in PC.
Related Concept Videos
The Tumor Microenvironment
Tumor Immunotherapy
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Abnormal Proliferation
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...

